Clindamycin phosphate | CAS#24729-96-2 | Ribosomal Translocation | Protein Synthesis Inhibitor

MedKoo Cat#: 540080 | Name: Clindamycin phosphate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clindamycin phosphate is a ribosomal translocation and protein synthesis inhibitor that displays efficacy against MRSA. It is also occasionally used to treat Plasmodium.

Chemical Structure

Clindamycin phosphate

CAS#24729-96-2 (phosphate)

Theoretical Analysis

MedKoo Cat#: 540080

Name: Clindamycin phosphate

CAS#: 24729-96-2 (phosphate)

Chemical Formula: C18H34ClN2O8PS

Exact Mass: 0.0000

Molecular Weight: 504.95

Elemental Analysis: C, 42.81; H, 6.79; Cl, 7.02; N, 5.55; O, 25.35; P, 6.13; S, 6.35

Price and Availability

Size	Price	Availability
5g	USD 350.00	2 Weeks
10g	USD 600.00	2 Weeks
25g	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

24729-96-2 (phosphate) 25507-04-4 (palmitate HCl) 21462-39-5 (HCl) 18323-44-9 (free) 58207-19-5 (HCl monohydrate)

Synonym

Clindamycin 2-Phosphate; U 28508; U-28508; U28508; DARE-BV1; NSC 618653; NSC618653; NSC-618653;

IUPAC/Chemical Name

(2R,3R,4S,5R,6R)-6-((1S,2S)-2-chloro-1-((2S,4R)-1-methyl-4-propylpyrrolidine-2-carboxamido)propyl)-4,5-dihydroxy-2-(methylthio)tetrahydro-2H-pyran-3-yl dihydrogen phosphate

InChi Key

UFUVLHLTWXBHGZ-MGZQPHGTSA-N

InChi Code

InChI=1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12+,13+,14-,15+,16+,18+/m0/s1

SMILES Code

CCC[C@@H]1C[C@@H](C(N[C@H]([C@@H](Cl)C)[C@@H]2[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O2)=O)N(C)C1

Appearance

White to off-white solid powder.

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 504.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gold MH, Korotzer A. Sub-group Analyses from a Trial of a Fixed Combination of Clindamycin Phosphate 1.2% and Benzoyl Peroxide 3.75% Gel for the Treatment of Moderate-to-severe Acne Vulgaris. J Clin Aesthet Dermatol. 2015 Dec;8(12):22-6. PubMed PMID: 26705445; PubMed Central PMCID: PMC4689508. 2: Stein Gold L. Efficacy and Tolerability of a Fixed Combination of Clindamycin Phosphate (1.2%) and Benzoyl Peroxide (3.75%) Aqueous Gel in Moderate and Severe Acne Vulgaris Subpopulations. J Drugs Dermatol. 2015 Sep;14(9):969-74. PubMed PMID: 26355615. 3: Ochsendorf F. Clindamycin phosphate 1.2% / tretinoin 0.025%: a novel fixed-dose combination treatment for acne vulgaris. J Eur Acad Dermatol Venereol. 2015 Jun;29 Suppl 5:8-13. doi: 10.1111/jdv.13185. Review. PubMed PMID: 26059820. 4: Del Rosso JQ. Clindamycin Phosphate 1.2%/Tretinoin 0.025% Gel for the Treatment of Acne Vulgaris: Which Patients are Most Likely to Benefit the Most? J Clin Aesthet Dermatol. 2015 Jun;8(6):19-23. PubMed PMID: 26155323; PubMed Central PMCID: PMC4479365. 5: Murray J, Potts A. The phototoxic and photoallergy potential of clindamycin phosphate 1.2%/ tretinoin 0.025% gel for facial acne: results of two single-center, evaluator-blinded, randomized, vehicle-controlled phase 1 studies in healthy volunteers. J Drugs Dermatol. 2014 Jan;13(1):16-22. PubMed PMID: 24385115. 6: Cook-Bolden FE. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. J Clin Aesthet Dermatol. 2015 May;8(5):28-32. PubMed PMID: 26029332; PubMed Central PMCID: PMC4445893. 7: Pariser DM, Rich P, Cook-Bolden FE, Korotzer A. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris. J Drugs Dermatol. 2014 Sep;13(9):1083-9. PubMed PMID: 25226009. 8: Modi PB, Shah NJ. Novel Stability-Indicating RP-HPLC Method for the Simultaneous Estimation of Clindamycin Phosphate and Adapalene along with Preservatives in Topical Gel Formulations. Sci Pharm. 2014 Jun 20;82(4):799-813. doi: 10.3797/scipharm.1404-01. Print 2014 Oct-Dec. PubMed PMID: 26171325; PubMed Central PMCID: PMC4475806. 9: Kawashima M, Hashimoto H, Alió Sáenz AB, Ono M, Yamada M. Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, active-controlled, parallel-group study. Br J Dermatol. 2015 Feb;172(2):494-503. doi: 10.1111/bjd.13265. Epub 2015 Jan 7. PubMed PMID: 25040180. 10: Cavera VL, Volski A, Chikindas ML. The Natural Antimicrobial Subtilosin A Synergizes with Lauramide Arginine Ethyl Ester (LAE), ε-Poly-L-lysine (Polylysine), Clindamycin Phosphate and Metronidazole, Against the Vaginal Pathogen Gardnerella vaginalis. Probiotics Antimicrob Proteins. 2015 Jun;7(2):164-71. doi: 10.1007/s12602-014-9183-1. PubMed PMID: 25588687. 11: Jones TM, Jasper S, Alió Sáenz AB. Bioavailability of Clindamycin From a New Clindamycin Phosphate 1.2%-Benzoyl Peroxide 3% Combination Gel. Clin Pharmacol Drug Dev. 2013 Jan;2(1):33-47. doi: 10.1002/cpdd.7. Epub 2013 Mar 4. PubMed PMID: 27121558. 12: Bhatia N, Pillai R. Randomized, Observer-blind, Split-face Compatibility Study with Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.75% gel and Facial Foundation Makeup. J Clin Aesthet Dermatol. 2015 Sep;8(9):25-32. PubMed PMID: 26430488; PubMed Central PMCID: PMC4587892. 13: Del Rosso JQ. Topical therapy for acne in women: is there a role for clindamycin phosphate-benzoyl peroxide gel? Cutis. 2014 Oct;94(4):177-82. Review. PubMed PMID: 25372252. 14: Ghaffari A, Manafi A, Moghimi HR. Clindamycin Phosphate Absorption from Nanoliposomal Formulations through Third-Degree Burn Eschar. World J Plast Surg. 2015 Jul;4(2):145-52. PubMed PMID: 26284183; PubMed Central PMCID: PMC4537606. 15: Dréno B, Bettoli V, Ochsendorf F, Layton AM, Perez M, Dakovic R, Gollnick H. Efficacy and safety of clindamycin phosphate 1.2%/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double-blind, parallel-group, phase III studies. Eur J Dermatol. 2014 Mar-Apr;24(2):201-9. doi: 10.1684/ejd.2014.2293. PubMed PMID: 24704684. 16: Nguyen TA, Eichenfield LF. Profile of clindamycin phosphate 1.2%/benzoyl peroxide 3.75% aqueous gel for the treatment of acne vulgaris. Clin Cosmet Investig Dermatol. 2015 Oct 29;8:549-54. doi: 10.2147/CCID.S79628. eCollection 2015. Review. PubMed PMID: 26604811; PubMed Central PMCID: PMC4629949. 17: Kilicarslan M, Gumustas M, Yildiz S, Baykara T. Preparation and characterization of chitosan-based spray-dried microparticles for the delivery of clindamycin phosphate to periodontal pockets. Curr Drug Deliv. 2014;11(1):98-111. PubMed PMID: 23947602. 18: Tamaddon L, Mostafavi SA, Karkhane R, Riazi-Esfahani M, Dorkoosh FA, Rafiee-Tehrani M. Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis. Adv Biomed Res. 2015 Jan 30;4:32. doi: 10.4103/2277-9175.150426. eCollection 2015. PubMed PMID: 25709997; PubMed Central PMCID: PMC4333484. 19: Tran le N, Dixit S, Park JH. Enantioseparation of basic chiral compounds on a clindamycin phosphate-silica/zirconia hybrid monolith by capillary electrochromatography. J Chromatogr A. 2014 Aug 22;1356:289-93. doi: 10.1016/j.chroma.2014.06.089. Epub 2014 Jul 5. PubMed PMID: 25037777. 20: Liang X, Du L, Su F, Parekh HS, Su W. The application of quantitative NMR for the facile, rapid and reliable determination of clindamycin phosphate in a conventional tablet formulation. Magn Reson Chem. 2014 Apr;52(4):178-82. doi: 10.1002/mrc.4048. Epub 2014 Jan 27. PubMed PMID: 24464591.